APRE - Aprea Therapeutics

-

$undefined

N/A

(N/A)

Aprea Therapeutics NASDAQ:APRE Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company's lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, Fast Track designation from the FDA for AML, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.

Location: | Website: www.aprea.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-13.26M

Cash

28.69M

Avg Qtr Burn

-3.39M

Short % of Float

0.26%

Insider Ownership

11.27%

Institutional Own.

42.17%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ATRN-119 Details
Solid tumor/s, Cancer

Phase 1

Data readout

APR-1051 Details
Solid tumor/s, Cancer

Phase 1

Data readout

Eprenetapopt (APR-246) + azacitidine Details
Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued

Eprenetapopt (APR-246) + Azacitidine Details
Blood disorder, Myelodysplastic syndrome

Failed

Discontinued

APR-548 + azacitidine Details
Mutant Myelodysplastic Syndromes

Failed

Discontinued